Recent

% | $
Quotes you view appear here for quick access.

FAR EAST ENERGY CORP Message Board

tdeank1 18 posts  |  Last Activity: Jul 15, 2016 7:41 AM Member since: Oct 13, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tdeank1 tdeank1 Jul 15, 2016 7:41 AM Flag

    you sure like that "slice and dice" comment JQ....errr JF

  • Reply to

    TODAY's NEWS!!!

    by georgejjl Jul 12, 2016 7:15 AM
    tdeank1 tdeank1 Jul 12, 2016 8:00 AM Flag

    Should Read PR, not process.....my Samsung auto correct. ..

  • Reply to

    TODAY's NEWS!!!

    by georgejjl Jul 12, 2016 7:15 AM
    tdeank1 tdeank1 Jul 12, 2016 7:59 AM Flag

    George it was a PROCESS not news, we had thus news a month ago...we all know the potential of avxl, we also know the challenges, like financing, and the blind study to get the drug to market, this is an emerging process, why not stop your incessant pumping, I realize you want wild swings because you are a momo, however you are clueless if you think this board effects PPS, which is the reason I can talk candidly even though I own a rather large stake in the company. ..

    Sentiment: Strong Buy

  • Reply to

    Double Blind Study?

    by emi_1114 Jul 8, 2016 2:42 PM
    tdeank1 tdeank1 Jul 8, 2016 2:54 PM Flag

    even stronger, in terms of internal validity, you can not "fake" dose dependency, whereas with double blind, there are still threats to internal validity...however the low sample size (32), along with the FDA not being fully behind adaptive trials for final approval of drugs, means they still need to move forward with phase III...

  • Reply to

    Double Blind Study?

    by emi_1114 Jul 8, 2016 2:42 PM
    tdeank1 tdeank1 Jul 8, 2016 2:51 PM Flag

    Not an accurate statement. You need to operationalize your word "counts". The adaptive design they used, and subsequent dose dependent curves, "count" for a lot, not just for safety and dosing (primary goal) but also for preliminary efficacy data (secondary goal). It "counts" on a lot of levels (partnerships, investment, financing, etc.) Although, not enough to get them through final FDA approval (although I have seen drugs in Europe get fast tracked for less), please stop your misinformation.

  • Reply to

    future

    by aiden.kennedy Jun 6, 2016 1:25 PM
    tdeank1 tdeank1 Jul 8, 2016 1:41 PM Flag

    *10% net royalties...

  • Reply to

    Message board cliche

    by tdeank1 Mar 11, 2016 1:51 PM
    tdeank1 tdeank1 Jul 8, 2016 1:32 PM Flag

    Shorts (none on this board, because there are none, or if there are, they are insignificant small time players) but the boiler room shorts, who live off of playing the odds of biotech failures, are about to react with fear, I imagine wee see an over reaction to the up side, testing the highs...

    Remember that Ivan...

  • Through 2019, good news, bulk of his potential earnings tied directly to PPS

    Sentiment: Strong Buy

  • Reply to

    ANAVEX 2-73…the building of a blockbuster…

    by tdeank1 Jan 15, 2016 2:16 PM
    tdeank1 tdeank1 Jul 7, 2016 2:39 PM Flag

    getting ready for the next entry...this July

    Sentiment: Strong Buy

  • Reply to

    Crazy afterhours volume going on.

    by riaguy Jun 24, 2016 5:00 PM
    tdeank1 tdeank1 Jun 25, 2016 8:42 AM Flag

    asking a question like that indicates you should NOT be investing

  • Reply to

    Crazy afterhours volume going on.

    by riaguy Jun 24, 2016 5:00 PM
    tdeank1 tdeank1 Jun 25, 2016 8:41 AM Flag

    I very seldom stop by anymore, the board is either full of 10 year old pumpers and a few bashers, or else this is the state of the general American intelligence, either way to depressing to read...

    Sentiment: Strong Buy

  • Reply to

    AAIC presentation

    by ajstaggs01 Jun 12, 2016 9:13 PM
    tdeank1 tdeank1 Jun 13, 2016 12:40 PM Flag

    finn....when you make these kind off statements it shows you are a short term momo...and ultimately 10xs worse than the bashers...

  • Reply to

    AAIC presentation

    by ajstaggs01 Jun 12, 2016 9:13 PM
    tdeank1 tdeank1 Jun 13, 2016 12:37 PM Flag

    it is an adaptive trial with a cross over design with a wash out period (i.e., time as a control)...even without placebo, there were some controls to improve internal validity for this trial... cross over designs are used to assess the order of effects of two or more factors (also known as multiple-treatment counterbalanced designs) in this case the 2 treatments were the 2 drug delivery systems...when applying a cross over design it is important to ensure a "washout period" or return to baseline between the adjacent treatment periods as a means to control for sequencing effects (multiple treatment interference)...these types of designs are ideal for eliminating issues associated with the between-subject variations and when a limited number of test subject are available...the two delivery systems and the multiple dose levels allow for more accurate examination of dose response...

    Sentiment: Strong Buy

  • tdeank1 tdeank1 Jun 7, 2016 4:13 PM Flag

    from an earlier post of mine...

    Adaptive Trial and Population PK design

    When they hired the design expert last year, I became much more confident in getting the drug to market...they will use an adaptive trial..."Adaptive trial designs allow for the modification of aspects of a study in a real-time, data-driven manner. Such modifications can include 1) stopping early for futility or success, 2) expanding sample size due to greater than expected data variability, or 3) allocating patients preferentially to regimens with a better therapeutic index. However, such potential adaptations must be defined before the trial starts to maintain the trial's validity and integrity. Given that the goal is to make adaptations as the study is ongoing, success is dependent on time to information (the earlier, the better) and recruitment speed relative to gathering and analyzing the observations required to adapt."

    At least two adaptations are frequently considered on an ongoing basis: 1) adapting the sample size due to variability in the observed data and the desired effect size, resulting in a dynamic termination rule (stopping the trial at the earliest time when a predefined level of confidence has been gained that either the dose-response and target dose are sufficiently well identified or that none of the doses achieves the desired treatment effect) and 2) adapting treatment allocation based on accruing response data, so that patients are preferentially allocated to informative doses later in the trial and/or unsafe or underperforming treatment arms are dropped.

    "The latter adaptation is important because early in drug development the nature of the dose-response relationship is often unknown: Is it a step function, linear, sigmoidal, or curvilinear?"

  • Reply to

    Adaptive trial and PK design

    by tdeank1 Nov 15, 2015 8:47 AM
    tdeank1 tdeank1 Jun 7, 2016 4:09 PM Flag

    try to listen to the presentation an hour before Misslings on adaptive trials....it will explain how the FDA is starting to come around to adaptive trials...

  • Revolutionizing Clinical Trials for Alzheimer’s: An International Perspective on Adaptive Clinical Trials

    Brain Health

    2:30 PM–3:45 PM Jun 6, 2016
    Dementia affects 47 million people globally, devastating lives and placing a huge burden on families, carers and society. Despite decades of research, there is still neither treatment nor cure for Alzheimer’s disease and success in clinical trials remains elusive. Pioneering projects on both sides of the Atlantic are working together to turn this situation around by running adaptive clinical trials – a first in Alzheimer’s research. In adaptive trials, multiple treatments are tested at the same time and the results analyzed continuously. This allows a faster assessment of treatments and the identification of groups of patients that respond best to them. In this session, leading dementia experts will share their experiences and trigger debate on how best to overcome the challenges to delivering successful clinical trials for much-needed Alzheimer’s treatments.

    Sentiment: Strong Buy

  • Reply to

    Zacks goes to Buy on AVXL

    by pauledockery Jun 2, 2016 2:08 PM
    tdeank1 tdeank1 Jun 2, 2016 3:29 PM Flag

    Read the full link I posted earlier...

  • lmkatDOTcom/2016-05-31-anavex-life-sciences-corp-avxl-lifted-to-buy-at-zacks-investment-research/

    Sentiment: Strong Buy

FEEC
0.00060.0000(0.00%)Nov 11 3:58 PMEST